Viral Hepatitis
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2006; 12(9): 1362-1366
Published online Mar 7, 2006. doi: 10.3748/wjg.v12.i9.1362
Table 1 Patients' characteristics
Patient (Gender/Age)DiagnosisIAHG ScoreAutoantibodies (titer)ALT (<0.85μmol/s.L)ALP (<2.15μmol/s.L)HAIFibrosisTherapyRes-
ANASMAANCAAMA(Ref. 6)(wk)ponse
pre-post-pre-post-pre-post-
BudesonideBudesonideBudesonide
First-line therapy
B.M-L. (F/65)AIH-PBC191280---15.180.227.121.44533241CR
D.B. (M/26)AIH14320---16.40.783.190.957nd436CR
D.C. (F/49)AIH22640---1.910.893.893.534nd524NR/AE
H-S.M. (F/31)AIH1716080--4.430.61.620.97nd250CR
K.M. (F/62)AIH14----3.453.597.866.295nd4122NR
L.M. (M/60)AIH16640640--4.10.35ndnd1nd082CR
N.G. (F/64)AIH-PBC122560--64010.730.387.531.63111082CR
S.T. (M/40)AIH12-->80-8.390.577.841.361nd024CR
T.H. (F/50)AIH19640160--3.386.771.541.749nd342NR
T.E. (F/49)AIH-PBC15-640-12802.270.584.211.61525112CR
Second-line therapy
B.R. (M/39)AIH14160---4.420.62.160.63621100CR
B.S. (F/25)AIH17160---16.480.414.891.38613116CR
D.H. (F/61)AIH-PBC14>2560---32.370.4511.911.2453432CR
F.C. (F/41)AIH1725602560-32010.10.554.60.886nd272CR
G.W. (M/68)AIH-PBC6----28.650.184.10.773nd4110CR
K.C. (F/40)AIH16640160--10.10.684.61.774nd150CR
S.H-D. (M/64)AIH-PSC112560---2.010.630.132.341180CR
S.U. (F/41)AIH-PSC141280---200.35.11.656nd1124CR